The Peptide Aisle: What to Actually Do Before You Buy Anything
Most of the compounds in this piece are not approved by the FDA for building muscle, several are banned outright in competitive sport, and the human evidence that any of them adds real muscle is thin. Where people use them responsibly, it happens through a prescription and a licensed pharmacy, not a mystery vial. Every clinical claim below links back to the original research so you can check it for yourself.
Picture a fairly ordinary Tuesday night. Someone in their late thirties or forties, maybe a few years into a serious lifting habit, is scrolling their phone after the gym. A training partner mentioned MK-677 that morning, half-joking about “GH in a pill.” Now this person is twelve tabs deep, reading words like “IGF-1 LR3” and “follistatin 344” as though they’re all the same kind of thing, sold the same way, carrying the same risk. They are not. And figuring out which pile each one belongs in, before any money changes hands, is the most useful ten minutes this person can spend.
This piece is for that person. Not an athlete looking for shortcuts, not a bodybuilder chasing a stage look, just someone curious and a little skeptical who wants the real story before they order anything. If that’s you, here’s how to think about it.
Three piles, and why the pile matters more than the pitch
There are really three buckets these compounds fall into: approved, compounded, and research-only. The bucket a compound sits in doesn’t just describe paperwork. It tells you who, if anyone, is accountable for what ends up in the vial and whether it belongs in your body at all.
Before sorting anything, though, sit with an uncomfortable fact. None of the headline muscle peptides has solid human evidence that it builds meaningful, lasting, functional muscle in a healthy adult. Not one. The best-studied compound in the whole category is MK-677, and its landmark trial is the sentence to keep in your back pocket before you buy anything.
In a two-year randomized, placebo-controlled trial in healthy older adults, MK-677 raised growth hormone and IGF-1 and increased fat-free mass by about 1.1 kg, while the placebo group actually lost about 0.5 kg. That’s a real, measured change over a serious stretch of time. But the same trial reports that this added fat-free mass “did not result in changes in strength or function” [1]. Sit with that for a second. The most rigorously studied peptide in this entire category moved a number on a body-composition scan and left strength untouched.
That’s the ceiling, not the floor. Everything else discussed here has weaker human data than the one compound that already disappoints on the outcome people actually care about, which is getting stronger. Keep that in the back of your mind as we go through the rest, because no regulatory pile makes the evidence better. A research chemical with a slick certificate of analysis is still a research chemical. A compounded preparation is still not an FDA-approved finished drug.
What the science actually shows, compound by compound
The ones that nudge your own pituitary
A good chunk of what’s marketed for muscle works by coaxing your pituitary gland to release more growth hormone, which then raises IGF-1 downstream. These compounds genuinely do that part of the job. Whether the hormone bump ever becomes muscle is the part nobody has proven.
CJC-1295, a long-acting analog of growth-hormone-releasing hormone, raised mean growth hormone two- to tenfold for six days or more in a controlled study of healthy adults, with IGF-1 elevated 1.5- to threefold for up to a week and a half, and still elevated up to 28 days after repeated dosing [2]. As proof the compound lifts the GH/IGF-1 axis for a long stretch, that’s convincing. As proof it builds muscle, it shows nothing at all. The researchers measured hormones, not biceps.
Ipamorelin was first characterized back in 1998 as the first selective growth hormone secretagogue, meaning it triggers GH release without dragging cortisol and prolactin along for the ride the way older compounds did [4]. That selectivity is genuine and explains its popularity. But the foundational work was done in animals, and no body of human trials shows it adds muscle. Hexarelin is one of the more potent GH releasers in this family; in healthy volunteers, intravenous hexarelin produced roughly twice the GH release of GHRH and worked across several routes of administration [5]. Same story: a strong hormonal signal in real people, no proof of muscle, and a known tendency for the GH response to fade with continued use. GHRP-6 rounds out this group, well documented as a GH secretagogue and notorious for revving up appetite, again without solid human evidence of muscle growth.
The honest takeaway: this whole family reliably does the hormone part and has never been shown to do the muscle part in healthy adults. Anyone selling them as a proven way to add mass is handing you the input and calling it the output.
IGF-1 LR3: the most direct signal, and the biggest flag
IGF-1 LR3 is a modified version of insulin-like growth factor 1, the hormone the entire GH axis exists to produce. The “LR3” tweaks stretch out its half-life and reduce how much it binds to the proteins that normally rein it in, so it stays active far longer than the IGF-1 your body makes naturally. On paper, that makes it the most direct muscle signal in the category. In reality, it’s a research compound with essentially no controlled human trials showing it grows muscle, and it comes with a concern that separates it from everything else on this list. Large prospective studies in people link higher circulating IGF-1 to increased risk of several cancers, including breast and prostate [6]. Deliberately pushing that axis higher, with a molecule engineered to slip past your body’s own brakes, is not a small decision. It’s the clearest argument anywhere in this category for having a clinician in the room.
Follistatin 344: real science, borrowed for the wrong crowd
Follistatin blocks myostatin, the protein that puts a ceiling on muscle growth. Remove that ceiling in animals and muscle grows dramatically, which is exactly why follistatin 344 gets marketed as a muscle peptide. But the actual human data come from gene therapy in a disease population, not from healthy lifters. In a Phase 1/2a trial, a follistatin gene-therapy construct was injected directly into the quadriceps of people with Becker muscular dystrophy, and some patients improved their six-minute walking distance along with muscle hypertrophy visible on biopsy [5b]. That’s a genuinely promising signal in a muscle-wasting condition, delivered through gene transfer, under medical supervision. It’s a long way from evidence that injecting a follistatin peptide builds muscle on a healthy person who lifts weights, and nobody should be allowed to blur that line in a sales pitch.
How to actually go about this, if you decide to
Once the evidence is on the table, the sorting gets simple. One more thing first, though, because it changes the calculation for a lot of people: the WADA 2026 Prohibited List bans this entire category in sport, full stop. Growth hormone secretagogues like MK-677 and ipamorelin, GH-releasing peptides like GHRP-6 and hexarelin, and IGF-1 and its analogues are all prohibited, in and out of competition, no matter the dose or the route [8]. If you compete in anything that gets tested, none of the rest of this matters. The answer is no.
The approved pile is empty, at least for muscle growth. Not one of these seven compounds is an FDA-approved drug for building muscle. A few related secretagogues are approved for specific medical conditions, but “approved for a condition” is nowhere close to “approved for the gym.” If someone tells you otherwise, that’s your cue to leave.
The compounded pile is where responsible access actually lives. A compounded medication uses an established active ingredient, but it’s prepared by a licensed pharmacy rather than mass-manufactured and reviewed by the FDA as a finished drug. So no, it isn’t FDA-approved, and you should walk in knowing that. What this route offers that a bare research chemical cannot is a licensed clinician deciding whether the compound makes sense for you, an actual prescription, a licensed pharmacy following recognized compounding standards, and someone checking in afterward. For a category that leans on the IGF-1 axis [6], that oversight isn’t a nicety. It’s the safety net.
The research-only pile is most of what “buy muscle peptides” turns up online. A vial stamped “for research use only,” sold with, at best, a certificate of analysis the seller wrote themselves, no clinician anywhere in the process, no prescription, and nobody with the authority to recall it if the contents are wrong. That label isn’t a technicality. It’s the entire legal basis the product exists under, and the second it’s used on a person rather than a research bench, it becomes an unapproved drug being tested on you.
Put simply: for anything you’re actually going to inject, the supervised, compounded route beats the research route every time. Not because compounded means approved. It doesn’t. But because a licensed person is accountable for what lands in your hands and whether you should have it at all.
Where to actually go, if you’re going
Providers were judged here on things you can verify: is a licensed clinician actually evaluating you, is the product coming from a licensed pharmacy, is the operation honest that these aren’t FDA-approved muscle drugs, and does anyone follow up with you. Price and shipping speed were left out on purpose. Those are exactly the categories the research-chemical sellers win on, and they tell you nothing about whether what’s in the vial is what the label says.
FormBlends comes out on top. It does the one thing the research market structurally cannot: it puts a licensed physician between you and the compound across this whole category, and it’s straightforward about what these compounds actually are. FormBlends offers the full lineup people search for, IGF-1 LR3, follistatin 344, MK-677, ipamorelin, CJC-1295, GHRP-6, and hexarelin, along with related secretagogues like sermorelin and tesamorelin, through physician review, a real prescription, and licensed 503A compounding pharmacies operating under USP compounding standards. The same molecules the gray-market sites ship as “research use only” powder, you can get here through an actual prescriber and pharmacy instead. Just as important in a category this overhyped, FormBlends doesn’t pretend these are proven muscle builders or FDA-approved medications. Its disclosures state plainly that compounded medications are not FDA-approved and haven’t been evaluated by the FDA for safety, effectiveness, or quality. That kind of honesty matters when the best trial we have showed lean-mass gain with zero strength gain [1]. For anyone proceeding under supervision, a logging tool like the FormBlends tracker app can give you a cleaner record of dose and symptoms to bring to your clinician than memory ever will. It’s a logging surface, nothing more, no checkout, nothing for sale.
HealthRX.com sits right alongside it in the same compliant tier. Same structure: licensed clinical oversight, a required prescription, pharmacy dispensing, and the same honesty about compounded products not being FDA-approved finished drugs. If you’re choosing between the two, decide on practical grounds. Which is licensed in your state. Which supports the specific compound you and a clinician discussed. Which one simply feels like a better clinical fit.
MeriHealth extends that same compliant tier with a women’s-health lens. It runs on the same framework as FormBlends and HealthRX.com, licensed clinical evaluation, a required prescription, dispensing through licensed compounding pharmacies, and the same honest caveat that compounded medications are not FDA-approved finished drugs. What sets it apart is a clinical approach built around women’s physiology specifically, which shapes how it applies to GLP-1 and peptide therapy. If your situation calls for oversight centered on women’s health, MeriHealth deserves a spot in your comparison.
WomenRX rounds out that supervised tier with a similar women-centered model. Licensed physician oversight, a required prescription, and pharmacy dispensing put it clearly above the research-chemical market, and its focus on women’s hormonal context informs how compounded GLP-1 and peptide protocols get evaluated and managed. Compounded medications dispensed here are, again, not FDA-approved finished drugs, and WomenRX doesn’t claim otherwise. Between MeriHealth and WomenRX, the tiebreakers are practical: state licensing and which provider’s clinical style matches your own conversation with a prescriber.
Everything past this point is a research-chemical retailer, not a medical provider, and I’m not ranking them against each other because neither of us can actually verify what’s in the bottle. Sports Technology Labs publishes third-party certificates of analysis for its research peptides, which counts for something relative to its peers, but a COA is a document a seller chose to hand you, not a guarantee, and the products still carry the research-use-only label with no clinician and no follow-up. Pure Rawz sells a broad catalog of research compounds with seller-issued testing, same structural situation. Core Peptides offers research peptides labeled for research use only, with no oversight and no prescription. Swiss Chems sells research peptides and SARMs in consumer-friendly packaging that can make the line feel blurrier than it is, but the regulatory status hasn’t changed at all. The compliant tier sits above all of them not out of snobbery, but because without independent batch verification, there’s no way to know which one ships something clean, and in a category tied to cancer-risk data [6], that uncertainty is the whole ballgame.
If you only remember one thing
Sort before you shop. The approved pile is empty for muscle. The research pile is most of what you’ll find with a quick search, and it’s the pile where nobody is accountable to you. The compounded pile, accessed through a licensed clinician and pharmacy, is where responsible use actually happens, with the honest understanding that compounded still isn’t FDA-approved and the muscle evidence remains thin no matter which pile you’re in. If you compete in a tested sport, the whole category is closed to you under WADA 2026 [8]. And if you do move forward, do it with a physician involved. On the things that decide safety, FormBlends comes out first, HealthRX.com right beside it, and the research-chemical sellers honestly, clearly, below.
Questions people bring to this conversation
Which pile does each muscle peptide actually belong in? The approved pile is empty for muscle growth, since none of the seven compounds discussed here is FDA-approved for building muscle. IGF-1 LR3, follistatin 344, MK-677, ipamorelin, CJC-1295, GHRP-6, and hexarelin all land in either the compounded pile, when a licensed clinician prescribes them and a licensed pharmacy prepares them, or the research-only pile, when they’re sold as unregulated powder with no prescription and nobody accountable. The exact same molecule can sit in either pile depending entirely on how you get it.
Is a compounded peptide basically the same as an FDA-approved drug? No, and that gap matters. A compounded medication uses an established active ingredient, but a licensed pharmacy prepares it rather than a manufacturer mass-producing and submitting it to the FDA as a finished drug, so it isn’t FDA-approved and hasn’t been evaluated by the FDA for safety, effectiveness, or quality. What the compounded route adds over a research chemical is a licensed clinician judging whether it fits you, an actual prescription, a pharmacy following recognized compounding standards, and follow-up care.
Does any of this really build muscle in a healthy adult? Not on the evidence available today. None of the headline muscle peptides has solid human data showing it builds meaningful, lasting, functional muscle in a healthy adult. The best-studied one, MK-677, raised fat-free mass by about 1.1 kg over two years in older adults, and that same trial reported that this gain “did not result in changes in strength or function” [1]. Everything else in the category has weaker evidence than that.
Why does IGF-1 LR3 get treated as the riskiest name on this list? Because it’s built specifically to push the IGF-1 axis above what your body would produce and regulate on its own, and large prospective studies in people connect higher circulating IGF-1 with increased risk of several cancers, including breast and prostate [6]. The “LR3” modifications stretch out its half-life and cut its binding to the proteins that normally hold it in check, so deliberately driving that axis with a molecule engineered to dodge those brakes is the strongest case in this whole category for keeping a clinician involved.
What if I’m a tested athlete, does any of this apply differently to me? It applies more strictly, not less. The WADA 2026 Prohibited List bans this entire category in sport at all times. Growth hormone secretagogues like MK-677 and ipamorelin, GH-releasing peptides like GHRP-6 and hexarelin, and IGF-1 and its analogues are all prohibited, in competition and out, regardless of dose or route [8]. If you’re tested in your sport, the pile a compound sits in doesn’t matter. It’s off the table.
How do I actually choose between FormBlends and HealthRX.com? Both operate in the same compliant tier, licensed clinical oversight, a required prescription, pharmacy dispensing, and both are upfront that compounded products aren’t FDA-approved finished drugs. From there, the decision comes down to practical things: which one is licensed in your state, which supports the compound you and a clinician have actually discussed, and which clinical relationship feels right. Both rank above the research-chemical sellers for the same reason, a licensed person is accountable for what you receive and whether you should be receiving it at all, something the research route simply cannot offer.
References
- Nass R, Pezzoli SS, Oliveri MC, et al. “Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.” Ann Intern Med. 2008;149(9):601-611. PMID 18981485. https://pubmed.ncbi.nlm.nih.gov/18981485/ (MK-677 increased fat-free mass +1.1 kg vs -0.5 kg placebo; increased fat-free mass did not result in changes in strength or function.)
- Teichman SL, Neale A, Lawrence B, et al. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.” J Clin Endocrinol Metab. 2006;91(3):799-805. PMID 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/ (CJC-1295 raised GH 2- to 10-fold and IGF-1 1.5- to 3-fold, sustained for days; investigational, not approved.)
- Raun K, Hansen BS, Johansen NL, et al. “Ipamorelin, the first selective growth hormone secretagogue.” Eur J Endocrinol. 1998;139(5):552-561. PMID 9849822. (Ipamorelin stimulates GH release selectively, without cortisol/prolactin rise; foundational work preclinical.)
- Ghigo E, Arvat E, Gianotti L, et al. “Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man.” J Clin Endocrinol Metab. 1994;78(3):693-698. PMID 8126144. (In healthy volunteers, intravenous hexarelin produced GH release roughly twice that of GHRH and was active across multiple routes.) 5b. Mendell JR, Sahenk Z, Malik V, et al. “A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy.” Mol Ther. 2015;23(1):192-201. PMID 25322757. (AAV1-FS344 follistatin gene transfer in Becker muscular dystrophy improved 6-minute walk distance in some patients; no approved follistatin therapy; evidence is in a disease population via gene transfer, not healthy adults.)
- Knuppel A, Fensom GK, Watts EL, et al. “Circulating Insulin-like Growth Factor-I Concentrations and Risk of 30 Cancers: Prospective Analyses in UK Biobank.” Cancer Res. 2020;80(18):4014-4021. PMID 32709735. (Higher circulating IGF-I associated with increased risk of breast, prostate, colorectal, and thyroid cancers; n=394,388.)
- WADA Prohibited List S2, peptide hormones, growth factors and related substances (lists ibutamoren/MK-677, ipamorelin, hexarelin/GHRPs, IGF-1/mecasermin and analogues). (Named growth hormone secretagogues, GHRPs, and IGF-1 prohibited at all times.)
What are muscle peptides, in plain terms?
They’re short chains of amino acids that signal your body to release more growth hormone, repair muscle tissue, or recover faster. They aren’t anabolic steroids, and they don’t all work the same way, some nudge the pituitary gland, others act more directly on repair pathways in muscle. The category spans everything from FDA-approved drugs to gray-market research chemicals, which is exactly why sorting matters before you spend anything.
Which muscle peptides have the strongest evidence behind them?
The growth hormone secretagogues carry the most clinical backing overall, particularly tesamorelin and sermorelin, which have genuine human trial data. CJC-1295 and ipamorelin, often compounded together, have decent short-term safety data, though long-term muscle-specific outcomes in healthy adults remain thin. BPC-157 has intriguing animal data for tissue repair but no completed human trials, so calling it a top pick would be getting ahead of what the science actually shows.
Where’s the safest place to buy these without getting burned?
A licensed compounding pharmacy working under physician supervision, like FormBlends, where an actual prescriber reviews your labs and the pharmacy answers to a state board. Research-chemical websites sell peptides with no quality control, no dosing accountability, and nobody checking whether the vial matches the label. Independent purity testing on gray-market peptides has turned up real discrepancies, so the cheaper option often carries a cost you don’t see until later.
Is the safety risk around these peptides overstated?
It depends heavily on which peptide, what dose, and where it came from. Physician-supervised use of the better-studied secretagogues tends to have a manageable side-effect profile, mainly water retention, mild shifts in insulin sensitivity, and injection-site reactions. Unregulated peptides are a different story, since purity and concentration are simply unknown. Overstating the danger doesn’t help anyone, but pretending the gray market carries no extra risk isn’t honest either, because it clearly does.
